Endogenous beta-carboline (6-methoxy-tetrahydro-beta-carboline)

Plain-language summaryIntrigue 40 / 100

Pinoline is a methoxylated tetrahydro-beta-carboline that the body makes endogenously, found in pineal gland and brain tissue. Biosynthetically it sits between the tryptamines (DMT, 5-MeO-DMT) and melatonin, which has fueled the long-disputed hypothesis that the pineal gland produces endogenous psychedelic compounds (the so-called DMT-pineal theory associated with Rick Strassman). Pharmacologically it is a weak reversible MAO-A inhibitor and a weak serotonin reuptake inhibitor. Concrete physiological function remains speculative, with most claims resting on tissue distribution and conjecture rather than controlled human studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

32/100

Niche endogenous beta-carboline with contested pineal biology and a very thin evidence base

Pinoline sits at a genuinely interesting intersection: it’s endogenous, it comes from the pineal gland, and it’s biosynthetically adjacent to the tryptamine family in a way that gets researchers excited about what it might be doing in vivo. We get that appeal. But when you actually dig into the pharmacology and the evidence base, the picture gets much murkier.

The mechanism is dual but weak. MAO-A inhibition (reversible, low potency) plus serotonin reuptake inhibition – neither of these is novel, and at the concentrations pinoline appears at endogenously, the functional significance is genuinely unclear. The compound has been implicated in the contested endogenous psychedelic hypothesis alongside DMT and 5-MeO-DMT, but this remains exactly that: a hypothesis. There’s no clean mechanistic story that says pinoline does X in the pineal at Y concentration and this matters for anything measurable.

The evidence problem is serious. Human pharmacokinetics are sparsely documented – the monograph says so directly, and thats not a small caveat, thats the whole ballgame for translational relevance. Most of the interesting preclinical work is old, small, and poorly replicated. There’s no equivalent of the Croatia-based BPC-157 group or the Khavinson lab anchoring a body of literature here. Multi-lab replication of the more interesting mechanistic claims is essentially absent.

Translational signal is correspondingly weak. Detection in pineal and brain tissue establishes endogenous presence but doesnt establish physiological role. The gap between found it there and it does this in humans remains very wide, and there’s no serious clinical program trying to close it. Contrast this with MOTS-c or SS-31, where the endogenous origin story is paired with a defined mitochondrial mechanism and real phase 2 data.

What pinoline has going for it is narrow but real probe value. If your lab is working on endogenous beta-carboline chemistry, MAO-A biology in a tryptaminergic context, or the broader contested field of pineal-derived signaling, pinoline is a useful reference compound. The biosynthetic relationship to melatonin and the structural adjacency to N,N-DMT give it genuine interest as a tool for mapping that chemical space. Thats a legitimate use case.

Honestly, the compound scores where it scores because the research space it occupies is real but small, the evidence is thin, the mechanism is not particularly elegant, and the translational gap is wide. For a lab specifically investigating beta-carboline pharmacology or endogenous pineal chemistry, it earns a place on the shelf. For anyone else, there are higher-signal targets in almost every adjacent category.

Novelty: 40
Mechanism promise: 32
In-category differentiation: 40
Evidence quality: 22
Translational signal: 18
Research bench value: 40

Rationale Weak dual MAO-A/SRI mechanism with low endogenous concentrations and unclear physiological role; evidence is sparse and poorly replicated, limiting scores heavily on evidence quality and translational signal; bench value is real but narrow, confined to labs specifically investigating beta-carboline or pineal-derived signaling chemistry.

Endogenous beta-carboline (6-methoxy-tetrahydro-beta-carboline)

An endogenous methoxylated tetrahydro-beta-carboline; a methylated tryptamine derivative implicated in pineal gland function.

Abstract

Pinoline (6-methoxy-1,2,3,4-tetrahydro-beta-carboline, 6-MeO-THBC; CAS 20684-89-1; molecular formula C12H14N2O; molecular weight 202.25) is an endogenous beta-carboline alkaloid identified in pineal gland and brain tissue. The compound is biosynthetically related to melatonin and to the tryptamines (DMT, 5-MeO-DMT) and is hypothesized to participate in endogenous psychoactivity (the contested DMT-pineal hypothesis). Pharmacologically, pinoline is a weak reversible MAO-A inhibitor and a serotonin reuptake inhibitor; the in vivo concentrations are low and its physiological role is incompletely characterized. Plasma half-life and pharmacokinetics in humans are sparsely documented. Used as a research probe for endogenous beta-carboline chemistry and pineal-gland-derived signaling.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-336Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Endogenous beta-carboline (6-methoxy-tetrahydro-beta-carboline)

Pinoline

Abstract

Read the full monograph